Table 3.
This table represents only the changes in therapeutic management occurred after PSMA-PET (stratified by clinical setting). Changes in the planned treatment prior to PSMA-PET were performed according a single-center multidisciplinary tumor board
| Changes occurred in planned therapy management, after PSMA-PET | FUP | S-PLND | SRT | ADT | SABR (MDT) | S-RP |
|---|---|---|---|---|---|---|
| % (n) | % (n) | % (n) | %(n) | % (n) | % (n) | % (n) |
|
Overall population 30.1% (53/176) |
8.0% (14/176) | 1.7% (3/176) | – | 13.6% (24/176) | 6.8% (12/176) | – |
|
Subgroup 1 34.2% (26/76) |
15.8% (12/76) | 2.6% (2/76) | – | 5.2% (4/76) | 10.5% (8/76) | – |
|
Subgroup 2 19.7% (15/76) |
– | – | – | 19.7% (15/76) | – | – |
|
Subgroup 3 50.0% (12/24) |
8.3% (2/24) | 4.2% (1/24) | – | 20.8% (5/24) | 16.7% (4/24) | – |
FUP Clinical follow-up with no therapies administered, S-PLND salvage pelvic lymph node dissection, SRT prostate-bed salvage radiotherapy, ADT androgen deprivation therapy, without other concomitant therapies, SABR stereotactic ablative radiotherapy, MDT metastasis directed therapy, MDT metastasis-directed therapy, S-RP salvage radical prostatectomy